Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

In a retrospective single-center cohort study, data suggest that patients with MPNs receiving ruxolitinib may experience weight gain and/or develop hypertension. Patients treated with ruxolitinib had a higher body mass index at 72 weeks compared with baseline (27.5 ± 5.5 kg/m2 vs. 25.8 ± 4.8 kg/m2; p < 0.001), as well as an increased prevalence of hypertension (64.7% at baseline vs. 69.1% at 72 weeks).

Scientific Reports